Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00658086 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

A Phase 2 study, sponsored by Alnylam Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
24
Enrollment target

NCT00658086: Completed Phase 2 study, sponsored by Alnylam Pharmaceuticals.

NCT00658086 is a Phase 2 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00658086, a Phase 2 study, has completed, sponsored by Alnylam Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target

Study Summary

To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected lung transplant patients

Interventions

  • DRUG normal saline
  • DRUG ALN-RSV01

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2008-04
Est. Completion 2009-06
Phase Phase 2
Alnylam Pharmaceuticals

49 total trials

What the finished NCT00658086 record still lists

NCT00658086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 2 interventions - of which normal saline is the first listed.

NCT00658086 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00658086 about?

NCT00658086 is a clinical study titled "Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)". To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected lung transplant patients

What is the current status of trial NCT00658086?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-04. Estimated completion is 2009-06.

What interventions are being tested in trial NCT00658086?

The interventions under investigation include: normal saline (DRUG), ALN-RSV01 (DRUG).

Who is sponsoring clinical trial NCT00658086?

This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00658086's enrollment target sits among peer trials

24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00658086, the US trial registry maintained by the National Library of Medicine. NCT00658086 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.